NovImmune raised €15M in a Series A round in May 2000. The company is based in Plan-les-Ouates, Switzerland. Investors in the round: LODH Immunology Fund, Novartis Venture Fund. Data as of 7 Aug 2026.
No source on record — unverified.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
